Feed BNGO
BN

Bionano Genomics, Inc.

BNGO · NASDAQ

$1.73 -1.14% (-$0.02)
1M +41.80%
Market Cap $19.9M
P/E Ratio -
Div. Yield -
ROE 78.78%
Piotroski F-Score Moderate
4/9
Valuation
100 /100
Cheap
P/B 0.63x
P/S 0.66x
P/FFO N/A
Growth
19 /100
Declining
Book val. growth 43.73%
Rev. growth 0.84%
FCF growth N/A
Profitability
19 /100
Weak
Net margin 106.58%
Op. margin 106.67%
FCF margin 67.87%
Quality
8 /100
Poor
ROE 78.78%
ROA 67.58%
Asset turnover 0.63x
Debt
69 /100
Low
Current ratio 2.48x
Int. coverage -149.69x
Debt/Equity 0.21x
Stability
20 /100
Unstable
Rev. volatility 23.95%
EPS volatility 80.71%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about BNGO
Online

About the company

Bionano Genomics (BNGO) is a biotechnology company focused on developing and commercializing its advanced genomic platform. This platform enables the study of the structure and variations of the human genome with high accuracy and detail. Bionano Genomics aims to provide tools for genetic research, genetic disease diagnostics, and personalized medicine. Bionano Genomics stock is suitable for investors interested in the biotechnology sector and innovative technologies in the field of genetics. Add Bionano Genomics stock to your watchlist on Bulios and stay informed about the latest advancements in genomics and biotechnology.

Sector

Healthcare

Industry

Medical - Instruments & Supplies

CEO

Albert A. Luderer

Employees

96

Headquarters

San Diego

Upcoming events

12 NOV

Earnings

Upcoming earnings report

52d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.